Stryker Corporation $SYK Shares Sold by Diversified Trust Co

Diversified Trust Co trimmed its position in Stryker Corporation (NYSE:SYK) by 14.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 16,832 shares of the medical technology company’s stock after selling 2,872 shares during the quarter. Diversified Trust Co’s holdings in Stryker were worth $5,531,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SYK. Baron Wealth Management LLC increased its position in shares of Stryker by 12.6% during the first quarter. Baron Wealth Management LLC now owns 1,407 shares of the medical technology company’s stock worth $462,000 after purchasing an additional 157 shares in the last quarter. Westmount Partners LLC lifted its holdings in Stryker by 19.0% in the 1st quarter. Westmount Partners LLC now owns 803 shares of the medical technology company’s stock valued at $264,000 after purchasing an additional 128 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its holdings in Stryker by 13.1% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 4,024 shares of the medical technology company’s stock valued at $1,322,000 after purchasing an additional 466 shares in the last quarter. J. Derek Lewis & Associates Inc. acquired a new stake in Stryker during the 4th quarter worth $234,000. Finally, Stance Capital LLC boosted its stake in Stryker by 4.8% during the 4th quarter. Stance Capital LLC now owns 12,517 shares of the medical technology company’s stock worth $4,399,000 after purchasing an additional 569 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent research reports. BTIG Research reduced their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Truist Financial reiterated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Stryker Stock Up 0.3%

Shares of NYSE:SYK opened at $308.62 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average of $313.81 and a two-hundred day moving average of $341.71. The stock has a market cap of $118.31 billion, a P/E ratio of 35.72, a PEG ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.